109 Phase I trial of a new anti-cytomegalovirus agent, (s)-1[3-hydroxy-2-(phosphonyl-methoxy)propyl]cytosine (HPMPC), in HIV-infected volunteers: M Wachsman, BG Petty, HS Jaffe, K Cundy, P Fisher, and PS Lietman. The Johns Hopkins University School of Medicine, Baltimore, MD, and Gilead Sciences, Inc., Foster City, CA, USA